Posts tagged Leerink
Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20.

Read More
Leerink ups Dova to OP, price target to $32

Leerink upgraded for Dova Pharmaceuticals (NASDAQ:DOVA) to “outperform” from “market perform” and raised its price target to $32 from $24 after competitor, Shionogi, announced results from a Phase 3 trial. Shares of Dova closed at $22.45 on Sept. 25.

Read More
Leerink starts Dova at MP

Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.

Read More
Leerink starts Mersana at OP

Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21.

Read More
Leerink starts Verona at buy

Leerink launched coverage of Verona Pharma (NADAQ:VRNA; AIM:VRP) with a “buy” rating and $22 price target after its recent cross-listing from the London Stock Exchange to NASDAQ. The stock closed at $13.52 on May 19.

Read More
Leerink starts Arena Pharma at OP

Leerink initiated coverage of Arena Pharmaceuticals (NASDAQ:ARNA) with an “outperform” rating and $5 price target. The stock closed at $1.15 on May 18.

Read More
Leerink upgrades Achillion to OP

Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17.

Read More